AstraZeneca Archives - Market Exclusive

Home Tags AstraZeneca

AstraZeneca (LON:AZN) had its Sell rating reiterated by UBS Group

ME Staff - April 23, 2019

AstraZeneca (LON:AZN) had its Buy rating reiterated by Deutsche Bank with...

ME Staff - April 8, 2019

AstraZeneca (LON:AZN) price target raised to GBX 6,400 by Liberum Capital

ME Staff - April 5, 2019

AstraZeneca (NYSE:AZN) gets downgraded to Sell by UBS Group

ME Staff - April 2, 2019

AstraZeneca (LON:AZN) had its Hold rating reiterated by Jefferies Financial Group...

ME Staff - March 29, 2019

AstraZeneca (LON:AZN) had its Sell rating reiterated by Goldman Sachs Group

ME Staff - March 18, 2019

AstraZeneca (LON:AZN) had its Hold rating reiterated by Jefferies Financial Group

ME Staff - March 14, 2019

AstraZeneca (LON:AZN) price target raised to GBX 5,000 by Goldman Sachs...

ME Staff - March 12, 2019

AstraZeneca (LON:AZN) had its Overweight rating reiterated by Barclays

ME Staff - March 11, 2019

AstraZeneca (LON:AZN) price target set to GBX 4,080 by Goldman Sachs...

ME Staff - February 26, 2019

12 3 4 Page 1 of 4

/* */

EDITOR PICKS

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

November 12, 2023

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

October 29, 2023

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

October 15, 2023

Weekly Biotech Report covering – Opko Health Inc (NYSE:OPK) Intercept...

April 11, 2016

Facebook Inc – (NASDAQ:FB) Might Be Moving Away From Its...

April 8, 2016

Biotechnology Movers: Here’s Why Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is Running Right...

November 8, 2017

ABOUT US

Market Exclusive offers the latest financial news and analysis for selected US stocks and securities. We are an investor driven research platform where new investment ideas from a exclusively selected group of seasoned investment analysts and qualified members from various disciplines are able to deliver their investment thesis’ across various industries and sectors. Our burgeoning team is comprised of individuals with strong backgrounds from various disciplines and businesses. Our goal is to provide an exclusive forum for contributors and users to leverage the knowledge base in order to make smarter investing decisions. At Market Exclusive, we believe that quality information from experienced well seasoned contributors provide our members with an edge that allows them to make wise investment choices. Market Exclusive is not a registered investment broker/dealer. The content on this site is for informational purposes only. Additionally, the content on this site does not represent the views of Market Exclusive and is solely a representation of the authors who publish them. Before investing in any security you should do your own due diligence and consult with a registered broker or financial advisor.

Tag: AstraZeneca

AstraZeneca (LON:AZN) had its Sell rating reiterated by UBS Group

AstraZeneca (LON:AZN) had its Buy rating reiterated by Deutsche Bank with...

AstraZeneca (LON:AZN) price target raised to GBX 6,400 by Liberum Capital

AstraZeneca (NYSE:AZN) gets downgraded to Sell by UBS Group

AstraZeneca (LON:AZN) had its Hold rating reiterated by Jefferies Financial Group...

AstraZeneca (LON:AZN) had its Sell rating reiterated by Goldman Sachs Group

AstraZeneca (LON:AZN) had its Hold rating reiterated by Jefferies Financial Group

AstraZeneca (LON:AZN) price target raised to GBX 5,000 by Goldman Sachs...

AstraZeneca (LON:AZN) had its Overweight rating reiterated by Barclays

AstraZeneca (LON:AZN) price target set to GBX 4,080 by Goldman Sachs...

EDITOR PICKS

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

POPULAR POSTS

Weekly Biotech Report covering – Opko Health Inc (NYSE:OPK) Intercept...

Facebook Inc – (NASDAQ:FB) Might Be Moving Away From Its...

Biotechnology Movers: Here’s Why Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is Running Right...

POPULAR CATEGORY